Clinical Trial Update: Stibium Metallicum Praeparatum 6x Versus Placebo in the Prevention of Paclitaxel-induced Peripheral Neurotoxicity [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Stibium Metallicum Praeparatum 6x vs placebo to prevent paclitaxel-induced peripheral neuropathy; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy

Drugs mentioned

• Stibium Metallicum Praeparatum 6x (Stibium metallicum praep. 6X)

Snippet

Sponsor: University of Bern | Conditions: Chemotherapy Induced Peripheral Neuropathy (CIPN) | Phase 3 | Status: NOT_YET_RECRUITING